Article Text

Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study
  1. Gwendoline Toulemonde1,
  2. Jean-Yves Scoazec2,
  3. Pierre Miossec1
  1. 1Department of Clinical Immunology and Rheumatology, Edouard Herriot hospital, University of Lyon, Lyon, France
  2. 2Department of Pathology, Edouard Herriot hospital, University of Lyon , Lyon, France
  1. Correspondence to Professor Pierre Miossec, Departments of Clinical Immunology and Rheumatology, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France; miossec{at}

Statistics from

Rheumatoid arthritis (RA) is a systemic disease, with extra-articular manifestations,1 including inflammatory liver disease.2 ,3 Our recent results indicate that elevated transaminase levels in RA patients on methotrexate (MTX) are rarely related to MTX-specific liver lesions (5%), but frequently to autoimmune hepatitis (AIH) histological lesions (41%).2 ,4 We have previously found that inhibition of tumour necrosis factor (TNF) with etanercept was well tolerated in patients with arthritis and hepatitis C virus infection.5 Since TNFα inhibition can control RA joint disease, we asked the question of a possible positive effect of TNFα inhibitors on RA-associated liver disease.

The objective of this proof of concept study was to evaluate the effect of 6 months of etanercept treatment on RA-associated AIH histological lesions.

Among a population of 1571 patients treated with MTX for chronic arthritis, 53 with persistent abnormal …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.